The Medical Letter on Drugs and Therapeutics
A Long-Acting Depot Formulation of Testosterone (Aveed)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved testosterone undecanoate (Aveed – Endo), an injectable depot formulation, for use in men with hypogonadism who require testosterone replacement therapy.

HYPOGONADISM — Failure of the testes to produce adequate amounts of testosterone can lead to loss of energy, decreased libido, erectile dysfunction, decreased axillary and pubic hair, loss of muscle mass, anemia, and osteoporosis. Testosterone serum concentrations decrease by about 1-2% per year after age 40. The normal range (usually 300-1000 ng/dL) is based on serum concentrations in young men. Older men with signs and symptoms of hypogonadism may have levels <200 ng/dL.

DOSAGE AND PHARMACOKINETICS — Each 3-mL vial of Aveed contains testosterone undecanoate 250 mg/mL in a mixture of 1500 mg of benzyl benzoate and 885 mg of refined castor oil. The recommended dosage is 750 mg injected intramuscularly at 0 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Long-Acting Depot Formulation of Testosterone (Aveed)
Article code: 1439b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian